Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/31366495http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/31366495http://www.w3.org/2000/01/rdf-schema#comment"

Background/aim

We investigated whether the expression of inositol 1, 4, 5-trisphosphate receptor-binding protein released with inositol 1, 4, 5-trisphosphate (IRBIT) in clinical gastric cancer (GC) patients could predict the therapeutic response to postoperative adjuvant chemotherapy.

Materials and methods

Immunohistochemistry was used to investigate IRBIT expression in 115 GC patients. To clarify whether IRBIT had a relationship with the therapeutic effects of chemotherapy, we compared two groups - 62 patients treated with postoperative adjuvant chemotherapy and 53 patients treated with postoperative adjuvant chemotherapy.

Results

Regarding the postoperative adjuvant chemotherapy-free group, we did not find any statistically significant correlation between clinicopathological features and recurrence regardless of the expression of IRBIT. In contrast, in the group receiving postoperative adjuvant chemotherapy, a significant association was found between IRBIT expression and both overall and disease-free survival.

Conclusion

IRBIT may be used as a useful predictive marker for chemotherapy."xsd:string
http://purl.uniprot.org/citations/31366495http://purl.org/dc/terms/identifier"doi:10.21873/anticanres.13569"xsd:string
http://purl.uniprot.org/citations/31366495http://purl.uniprot.org/core/author"Ogata K."xsd:string
http://purl.uniprot.org/citations/31366495http://purl.uniprot.org/core/author"Kimura A."xsd:string
http://purl.uniprot.org/citations/31366495http://purl.uniprot.org/core/author"Sohda M."xsd:string
http://purl.uniprot.org/citations/31366495http://purl.uniprot.org/core/author"Nakazawa N."xsd:string
http://purl.uniprot.org/citations/31366495http://purl.uniprot.org/core/author"Shirabe K."xsd:string
http://purl.uniprot.org/citations/31366495http://purl.uniprot.org/core/author"Saeki H."xsd:string
http://purl.uniprot.org/citations/31366495http://purl.uniprot.org/core/author"Ide M."xsd:string
http://purl.uniprot.org/citations/31366495http://purl.uniprot.org/core/author"Kuwano H."xsd:string
http://purl.uniprot.org/citations/31366495http://purl.uniprot.org/core/author"Yokobori T."xsd:string
http://purl.uniprot.org/citations/31366495http://purl.uniprot.org/core/author"Kogure N."xsd:string
http://purl.uniprot.org/citations/31366495http://purl.uniprot.org/core/author"Ubukata Y."xsd:string
http://purl.uniprot.org/citations/31366495http://purl.uniprot.org/core/author"Baatar S."xsd:string
http://purl.uniprot.org/citations/31366495http://purl.uniprot.org/core/date"2019"xsd:gYear
http://purl.uniprot.org/citations/31366495http://purl.uniprot.org/core/name"Anticancer Res"xsd:string
http://purl.uniprot.org/citations/31366495http://purl.uniprot.org/core/pages"4111-4116"xsd:string
http://purl.uniprot.org/citations/31366495http://purl.uniprot.org/core/title"Low IRBIT Levels Are Associated With Chemo-resistance in Gastric Cancer Patients."xsd:string
http://purl.uniprot.org/citations/31366495http://purl.uniprot.org/core/volume"39"xsd:string
http://purl.uniprot.org/citations/31366495http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/31366495
http://purl.uniprot.org/citations/31366495http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/31366495
http://purl.uniprot.org/uniprot/#_A0A024R0A8-mappedCitation-31366495http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/31366495
http://purl.uniprot.org/uniprot/#_O43210-mappedCitation-31366495http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/31366495
http://purl.uniprot.org/uniprot/#_Q2NKW8-mappedCitation-31366495http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/31366495
▶